|
Variables
|
BCS (%)
|
Mastectomy (%)
|
Radical Mastectomy (%)
|
χ2
|
P-value
|
|---|
|
Race
| | | | | |
|
White
|
297 (78.0%)
|
204 (80.0%)
|
467 (76.7%)
| | |
|
Black
|
57 (15.0%)
|
38 (14.9%)
|
95 (15.6%)
|
2.12
|
0.714
|
|
Other
|
27 (7.0%)
|
13 (5.1%)
|
47 (7.7%)
| | |
|
Age
| | | | | |
|
≤ 35
|
13 (3.4%)
|
16 (6.3%)
|
38 (6.2%)
| | |
|
35 < age < 60
|
181 (47.5%)
|
132 (51.8%)
|
318 (52.2%)
|
8.373
|
0.079
|
|
≥ 60
|
187 (49.1%)
|
107 (42.0%)
|
253 (41.5%)
| | |
|
Grade
| | | | | |
|
1
|
34 (8.9%)
|
20 (7.8%)
|
45 (7.4%)
|
6.528
|
0.163
|
|
2
|
173 (45.4%)
|
129 (50.6%)
|
258 (42.4%)
| | |
|
3–4
|
174 (45.7%)
|
106 (41.6%)
|
306 (50.2%)
| | |
|
Laterality
| | | | | |
|
Left
|
209 (54.9%)
|
130 (51.0%)
|
317 (52.1%)
|
1.115
|
0.573
|
|
Right
|
172 (45.1%)
|
125 (49.0%)
|
292 (48.0%)
| | |
|
Marital
| | | | | |
|
Married
|
206 (54.1%)
|
138 (54.1%)
|
318 (52.2%)
| | |
|
Unmarried
|
175 (45.9%)
|
117 (45.9%)
|
291 (47.8%)
|
0.438
|
0.803
|
|
Ethnic origin
| | | | | |
|
Spanish-Hispanic-Latino
|
43 (11.3%)
|
23 (9.0%)
|
70 (11.5%)
|
1.205
|
0.547
|
|
Non-Spanish-Hispanic-Latino
|
338 (88.7%)
|
232 (91.0%)
|
539 (88.5%)
| | |
|
Histology
| | | | | |
|
IDC
|
326 (85.6%)
|
201 (80.0%)
|
49 (77.0%)
|
5.163
|
0.076
|
|
Non-IDC
|
55 (14.4%)
|
54 (20.0%)
|
113 (33.0%)
| | |
|
T stage
| | | | | |
|
T1
|
91 (23.9%)
|
21 (8.2%)
|
41 (6.7%)
|
158,845
|
< 0.001
|
|
T2
|
22 (58.3%)
|
109 (42.7%)
|
238 (39.10%)
| | |
|
T3
|
37 (9.7%)
|
59 (23.1%)
|
146 (24%)
| | |
|
T4
|
31 (8.1%)
|
66 (25.9%)
|
184 (30.20%)
| | |
|
N stage
| | | | | |
|
N0
|
126 (33.1%)
|
52 (20.4%)
|
30 (4.9%)
| | |
|
N1
|
133 (34.9%)
|
124 (48.6%)
|
206 (33.80%)
|
192.317
|
< 0.001
|
|
N2
|
67 (17.6%)
|
41 (16.10%)
|
153 (25.10%)
| | |
|
N3
|
55 (14.4%)
|
38 (14.90%)
|
220 (36.10%)
| | |
|
Radiation
| | | | | |
|
Yes
|
22 (60.1%)
|
124 (48.6%)
|
351 (57.60%)
| | |
|
No
|
15 (39.9%)
|
131 (51.40%)
|
258 (42.40%)
|
8.765
|
0.012
|
|
Chemotherapy
| | | | | |
|
Yes
|
20 (54.9%)
|
171 (69.50%)
|
423 (67.10%)
| | |
|
No
|
17 (45.1%)
|
84 (30.50%)
|
186 (32.90%)
|
22.744
|
< 0.001
|
|
Subtype
| | | | | |
|
ER + /HER2−
|
276 (72.4%)
|
177 (69.4%)
|
416 (68.3%)
| | |
|
ER + /HER2 +
|
54 (14.2%)
|
34 (13.3%)
|
101 (16.6%)
|
6.514
|
0.368
|
|
HER2 +
|
15 (3.9%)
|
11 (4.3%)
|
35 (5.7%)
| | |
|
TNBC
|
36 (9.4%)
|
33 (12.9%)
|
57 (9.4%)
| | |
|
ER
| | | | | |
|
Positive
|
329 (86.4%)
|
207 (81.2%)
|
514 (84.4%)
|
3.101
|
0.212
|
|
Negative
|
52 (13.6%)
|
48 (18.8%)
|
95 (15.6%)
| | |
|
PR
| | | | | |
|
Positive
|
281 (73.8%)
|
176 (69.0%)
|
429 (70.4%)
|
1.97
|
0.373
|
|
Negative
|
100 (26.2%)
|
79 (31.0%)
|
180 (29.6%)
| | |
|
HER2
| | | | | |
|
Positive
|
69 (18.1%)
|
45 (17.6%)
|
136 (22.3%)
|
3.786
|
0.151
|
|
Negative
|
312 (81.9%)
|
210 (82.4%)
|
473 (77.7%)
| | |
- ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer
